申请人:The Upjohn Company
公开号:US05547950A1
公开(公告)日:1996-08-20
A compound of structural Formula I: ##STR1## or pharmaceutically acceptable salts thereof wherein: each n is independently 1 to 3; Y is chosen from a-n as defined herein; wherein each occurrence of said C.sub.1-6 alkyl may be substituted with one or more F, Cl, Br, I, OR.sup.1, CO.sub.2 R.sup.1, CN, SR.sup.1, or R.sup.1 (where R.sup.1 is a hydrogen or C.sub.1-4 alkyl); X and Z are independently C.sub.1-6 alkyl, C.sub.3-12 cycloalkyl or hydrogen, or X and Z form a C.sub.0-3 bridging group, preferably X and Z are hydrogen; U, V and W are independently C.sub.1-6 alkyl, F, Cl, Br, hydrogen or a C.sub.1-6 alkyl substituted with one or more of F, Cl, Br or I, preferably U and V are F and W is hydrogen; R is hydrogen, C.sub.1-12 alkyl, C.sub.3-12 cycloalkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkyl substituted with one or more F, Cl, Br, I or OH; and q is 0 to 4 inclusive. Oxazolidinone derivatives possessing a substituted diazine moiety bonded to the N-aryl ring are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including multiply-resistant staphylococci and streptococci, as well as anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms such as Mycobacterium tuberculosis and Mycobacterium avium.
结构式I的化合物:##STR1##或其药用可接受的盐,其中:每个n独立地为1到3;Y从a-n中选择,如此处所定义;其中所述的每个C.sub.1-6烷基的每次出现可以用一个或多个F、Cl、Br、I、OR.sup.1、CO.sub.2R.sup.1、CN、SR.sup.1或R.sup.1(其中R.sup.1是氢或C.sub.1-4烷基)替代;X和Z独立地为C.sub.1-6烷基、C.sub.3-12环烷基或氢,或X和Z形成一个C.sub.0-3桥联基,优选X和Z为氢;U、V和W独立地为C.sub.1-6烷基、F、Cl、Br、氢或一个或多个F、Cl、Br或I取代的C.sub.1-6烷基,优选U和V为F,W为氢;R为氢、C.sub.1-12烷基、C.sub.3-12环烷基、C.sub.1-6烷氧基、一个或多个F、Cl、Br、I或OH取代的C.sub.1-6烷基;q为0到4(包括4)。具有与N-芳基环结合的取代二嗪基团的噁唑烷酮衍生物是有用的抗微生物药剂,对许多人类和兽医病原体有效,包括多重耐药葡萄球菌和链球菌,以及厌氧生物,如拟杆菌和梭菌属,以及耐酸生物,如结核分枝杆菌和分枝杆菌。